AstraZeneca said its vaccine, developed in collaboration with the University of Oxford showed an average 70% effectiveness in preventing COVID-19.
AstraZeneca said its vaccine, developed in collaboration with the University of Oxford showed an average of 70% effectiveness in preventing COVID-19.
According to AstraZeneca, its clinical trials in the UK and Brazil showed the vaccine stopping people from developing symptoms in 70% of 131 cases on average.
Results from the final trial have also shown its efficiency rose up to 90% if a lower first dose is used.
Scientists were not sure why, but they assumed that giving the immune system just a small first glimpse of the virus’s spike protein may be a better way to activate it the second time.
The other dosing regimen has shown that the vaccine provides 62% efficacy when given as two full doses at least one month apart.
“These findings show that we have an effective vaccine that will save many lives,” said professor Andrew Pollard, chief investigator of the Oxford Vaccine Trial.
More than 23,000 volunteers took part in the trials in the U.K. and Brazil but more data will be collected from around the world in the coming weeks.
The results of the incoming data could alter the average efficacy rate and help to establish the duration of the vaccine’s protection.
Pascal Soriot, CEO of AstraZeneca, said the progress of their vaccine marked an “important milestone” in the fight against the global COVID-19 pandemic.
© Fourth Estate® — All Rights Reserved.
This material may not be published, broadcast, rewritten or redistributed.